New

Blood Cancer Drugs Market

2021

Blood Cancer Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Blood Cancer Types ( Leukemia, Lymphoma, Myeloma ); Drugs ( Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Others ); Treatment Approaches ( Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic )

| Report Code: TIPRE00019607 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Market Insights

Blood Cancer Drugs Market 2028 Blood Cancer Types, Drugs, Treatment Approaches | The Insight Partners

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of blood cancer are leukemia, lymphoma, and multiple myeloma. Also called hematologic cancer. The drugs such as bosulif (bosutinib), bosutinib., busulfan, busulfex (busulfan) are used in blood cancer treatment.

MARKET DYNAMICS

The blood cancer drugs market is driving due to the growing death incidences and increasing prevalence of blood cancer cases. Moreover rising prevalence of chronic conditions such autoimmune diseases, cancers etc will further offer lucrative opportunities in market growth.

MARKET SCOPE

The "Blood Cancer Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with/ a special focus on the global market trend analysis. The report aims to provide an overview of Blood Cancer Drugs market with detailed market segmentation blood cancer type, drugs, Treatment approaches, . The blood cancer drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in blood cancer drugs market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Blood Cancer Drugs market is segmented on the basis of blood cancer type, drugs, Treatment approaches. Based on blood cancer type, the market is segmented as Leukemia, Lymphoma, Myeloma. Based on drugs, the market is segmented as Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Others. Based on Treatment Approaches, the market is segmented as Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Blood Cancer Drugs Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Blood Cancer Drugs Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Blood Cancer Drugs Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely, North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social, and technological factors effecting the Blood Cancer Drugs Market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Blood Cancer Drugs Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Blood Cancer Drugs Market are anticipated to have lucrative growth opportunities in the future with the rising demand for Blood Cancer Drugs Market in the global market. Below mentioned is the list of few companies engaged in the Blood Cancer Drugs market.

The report also includes the profiles of key players in Blood Cancer Drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   Johnson & Johnson Inc.
  •   Amgen Inc.
  •   Bayer AG.
  •   Pfizer, Inc.]
  •   AbbVie Inc.
  •   Roche Holding AG.
  •   Celgene Corporation
  •   AstraZeneca
  •   Novartis AG
  •   GlaxoSmithKline PLC

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Blood Cancer Drugs Market- - By Blood Cancer Types
1.3.2 Blood Cancer Drugs Market- - By Drugs
1.3.3 Blood Cancer Drugs Market- - By Treatment Approaches
1.3.4 Blood Cancer Drugs Market- - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. BLOOD CANCER DRUGS MARKET- LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. BLOOD CANCER DRUGS MARKET- - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. BLOOD CANCER DRUGS MARKET- - GLOBAL MARKET ANALYSIS
6.1. BLOOD CANCER DRUGS - GLOBAL MARKET OVERVIEW
6.2. BLOOD CANCER DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. BLOOD CANCER DRUGS MARKET- - REVENUE AND FORECASTS TO 2028 - BLOOD CANCER TYPES
7.1. OVERVIEW
7.2. BLOOD CANCER TYPES MARKET FORECASTS AND ANALYSIS
7.3. LEUKEMIA
7.3.1. Overview
7.3.2. Leukemia Market Forecast and Analysis
7.4. LYMPHOMA
7.4.1. Overview
7.4.2. Lymphoma Market Forecast and Analysis
7.5. MYELOMA
7.5.1. Overview
7.5.2. Myeloma Market Forecast and Analysis
8. BLOOD CANCER DRUGS MARKET- - REVENUE AND FORECASTS TO 2028 - DRUGS
8.1. OVERVIEW
8.2. DRUGS MARKET FORECASTS AND ANALYSIS
8.3. RITUAXAN/MABTHERA (RITUXIMAB)
8.3.1. Overview
8.3.2. Rituaxan/Mabthera (Rituximab) Market Forecast and Analysis
8.4. GLEEVAC/GLIVEC (IMATINIB)
8.4.1. Overview
8.4.2. Gleevac/Glivec (Imatinib) Market Forecast and Analysis
8.5. REVLIMID (LENALIDOMIDE)
8.5.1. Overview
8.5.2. Revlimid (Lenalidomide) Market Forecast and Analysis
8.6. VELCADE (BORTEZOMIB)
8.6.1. Overview
8.6.2. Velcade (Bortezomib) Market Forecast and Analysis
8.7. TASIGNA (NILOTINIB)
8.7.1. Overview
8.7.2. Tasigna (Nilotinib) Market Forecast and Analysis
8.8. POMALYST (POMALIDOMIDE)
8.8.1. Overview
8.8.2. Pomalyst (Pomalidomide) Market Forecast and Analysis
8.9. VIDAZA (AZACITIDINE)
8.9.1. Overview
8.9.2. Vidaza (Azacitidine) Market Forecast and Analysis
8.10. KYPROLIS (CARFILZOMIB)
8.10.1. Overview
8.10.2. Kyprolis (Carfilzomib) Market Forecast and Analysis
8.11. ADCETRIS (BRENTUXIMAB VEDOTIN)
8.11.1. Overview
8.11.2. Adcetris (Brentuximab Vedotin) Market Forecast and Analysis
8.12. OTHERS
8.12.1. Overview
8.12.2. Others Market Forecast and Analysis
9. BLOOD CANCER DRUGS MARKET- - REVENUE AND FORECASTS TO 2028 - TREATMENT APPROACHES
9.1. OVERVIEW
9.2. TREATMENT APPROACHES MARKET FORECASTS AND ANALYSIS
9.3. CHEMOTHERAPEUTIC
9.3.1. Overview
9.3.2. Chemotherapeutic Market Forecast and Analysis
9.4. MABS/TARGETED THERAPIES
9.4.1. Overview
9.4.2. MAbs/Targeted Therapies Market Forecast and Analysis
9.5. IMMUNOTHERAPEUTIC
9.5.1. Overview
9.5.2. Immunotherapeutic Market Forecast and Analysis
10. BLOOD CANCER DRUGS MARKET- REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Blood Cancer Drugs Market- Overview
10.1.2 North America Blood Cancer Drugs Market- Forecasts and Analysis
10.1.3 North America Blood Cancer Drugs Market- Forecasts and Analysis - By Blood Cancer Types
10.1.4 North America Blood Cancer Drugs Market- Forecasts and Analysis - By Drugs
10.1.5 North America Blood Cancer Drugs Market- Forecasts and Analysis - By Treatment Approaches
10.1.6 North America Blood Cancer Drugs Market- Forecasts and Analysis - By Countries
10.1.6.1 United States Blood Cancer Drugs Market-
10.1.6.1.1 United States Blood Cancer Drugs Market- by Blood Cancer Types
10.1.6.1.2 United States Blood Cancer Drugs Market- by Drugs
10.1.6.1.3 United States Blood Cancer Drugs Market- by Treatment Approaches
10.1.6.2 Canada Blood Cancer Drugs Market-
10.1.6.2.1 Canada Blood Cancer Drugs Market- by Blood Cancer Types
10.1.6.2.2 Canada Blood Cancer Drugs Market- by Drugs
10.1.6.2.3 Canada Blood Cancer Drugs Market- by Treatment Approaches
10.1.6.3 Mexico Blood Cancer Drugs Market-
10.1.6.3.1 Mexico Blood Cancer Drugs Market- by Blood Cancer Types
10.1.6.3.2 Mexico Blood Cancer Drugs Market- by Drugs
10.1.6.3.3 Mexico Blood Cancer Drugs Market- by Treatment Approaches
10.2. EUROPE
10.2.1 Europe Blood Cancer Drugs Market- Overview
10.2.2 Europe Blood Cancer Drugs Market- Forecasts and Analysis
10.2.3 Europe Blood Cancer Drugs Market- Forecasts and Analysis - By Blood Cancer Types
10.2.4 Europe Blood Cancer Drugs Market- Forecasts and Analysis - By Drugs
10.2.5 Europe Blood Cancer Drugs Market- Forecasts and Analysis - By Treatment Approaches
10.2.6 Europe Blood Cancer Drugs Market- Forecasts and Analysis - By Countries
10.2.6.1 Germany Blood Cancer Drugs Market-
10.2.6.1.1 Germany Blood Cancer Drugs Market- by Blood Cancer Types
10.2.6.1.2 Germany Blood Cancer Drugs Market- by Drugs
10.2.6.1.3 Germany Blood Cancer Drugs Market- by Treatment Approaches
10.2.6.2 France Blood Cancer Drugs Market-
10.2.6.2.1 France Blood Cancer Drugs Market- by Blood Cancer Types
10.2.6.2.2 France Blood Cancer Drugs Market- by Drugs
10.2.6.2.3 France Blood Cancer Drugs Market- by Treatment Approaches
10.2.6.3 Italy Blood Cancer Drugs Market-
10.2.6.3.1 Italy Blood Cancer Drugs Market- by Blood Cancer Types
10.2.6.3.2 Italy Blood Cancer Drugs Market- by Drugs
10.2.6.3.3 Italy Blood Cancer Drugs Market- by Treatment Approaches
10.2.6.4 Spain Blood Cancer Drugs Market-
10.2.6.4.1 Spain Blood Cancer Drugs Market- by Blood Cancer Types
10.2.6.4.2 Spain Blood Cancer Drugs Market- by Drugs
10.2.6.4.3 Spain Blood Cancer Drugs Market- by Treatment Approaches
10.2.6.5 United Kingdom Blood Cancer Drugs Market-
10.2.6.5.1 United Kingdom Blood Cancer Drugs Market- by Blood Cancer Types
10.2.6.5.2 United Kingdom Blood Cancer Drugs Market- by Drugs
10.2.6.5.3 United Kingdom Blood Cancer Drugs Market- by Treatment Approaches
10.2.6.6 Rest of Europe Blood Cancer Drugs Market-
10.2.6.6.1 Rest of Europe Blood Cancer Drugs Market- by Blood Cancer Types
10.2.6.6.2 Rest of Europe Blood Cancer Drugs Market- by Drugs
10.2.6.6.3 Rest of Europe Blood Cancer Drugs Market- by Treatment Approaches
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Blood Cancer Drugs Market- Overview
10.3.2 Asia-Pacific Blood Cancer Drugs Market- Forecasts and Analysis
10.3.3 Asia-Pacific Blood Cancer Drugs Market- Forecasts and Analysis - By Blood Cancer Types
10.3.4 Asia-Pacific Blood Cancer Drugs Market- Forecasts and Analysis - By Drugs
10.3.5 Asia-Pacific Blood Cancer Drugs Market- Forecasts and Analysis - By Treatment Approaches
10.3.6 Asia-Pacific Blood Cancer Drugs Market- Forecasts and Analysis - By Countries
10.3.6.1 Australia Blood Cancer Drugs Market-
10.3.6.1.1 Australia Blood Cancer Drugs Market- by Blood Cancer Types
10.3.6.1.2 Australia Blood Cancer Drugs Market- by Drugs
10.3.6.1.3 Australia Blood Cancer Drugs Market- by Treatment Approaches
10.3.6.2 China Blood Cancer Drugs Market-
10.3.6.2.1 China Blood Cancer Drugs Market- by Blood Cancer Types
10.3.6.2.2 China Blood Cancer Drugs Market- by Drugs
10.3.6.2.3 China Blood Cancer Drugs Market- by Treatment Approaches
10.3.6.3 India Blood Cancer Drugs Market-
10.3.6.3.1 India Blood Cancer Drugs Market- by Blood Cancer Types
10.3.6.3.2 India Blood Cancer Drugs Market- by Drugs
10.3.6.3.3 India Blood Cancer Drugs Market- by Treatment Approaches
10.3.6.4 Japan Blood Cancer Drugs Market-
10.3.6.4.1 Japan Blood Cancer Drugs Market- by Blood Cancer Types
10.3.6.4.2 Japan Blood Cancer Drugs Market- by Drugs
10.3.6.4.3 Japan Blood Cancer Drugs Market- by Treatment Approaches
10.3.6.5 South Korea Blood Cancer Drugs Market-
10.3.6.5.1 South Korea Blood Cancer Drugs Market- by Blood Cancer Types
10.3.6.5.2 South Korea Blood Cancer Drugs Market- by Drugs
10.3.6.5.3 South Korea Blood Cancer Drugs Market- by Treatment Approaches
10.3.6.6 Rest of Asia-Pacific Blood Cancer Drugs Market-
10.3.6.6.1 Rest of Asia-Pacific Blood Cancer Drugs Market- by Blood Cancer Types
10.3.6.6.2 Rest of Asia-Pacific Blood Cancer Drugs Market- by Drugs
10.3.6.6.3 Rest of Asia-Pacific Blood Cancer Drugs Market- by Treatment Approaches
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Blood Cancer Drugs Market- Overview
10.4.2 Middle East and Africa Blood Cancer Drugs Market- Forecasts and Analysis
10.4.3 Middle East and Africa Blood Cancer Drugs Market- Forecasts and Analysis - By Blood Cancer Types
10.4.4 Middle East and Africa Blood Cancer Drugs Market- Forecasts and Analysis - By Drugs
10.4.5 Middle East and Africa Blood Cancer Drugs Market- Forecasts and Analysis - By Treatment Approaches
10.4.6 Middle East and Africa Blood Cancer Drugs Market- Forecasts and Analysis - By Countries
10.4.6.1 South Africa Blood Cancer Drugs Market-
10.4.6.1.1 South Africa Blood Cancer Drugs Market- by Blood Cancer Types
10.4.6.1.2 South Africa Blood Cancer Drugs Market- by Drugs
10.4.6.1.3 South Africa Blood Cancer Drugs Market- by Treatment Approaches
10.4.6.2 Saudi Arabia Blood Cancer Drugs Market-
10.4.6.2.1 Saudi Arabia Blood Cancer Drugs Market- by Blood Cancer Types
10.4.6.2.2 Saudi Arabia Blood Cancer Drugs Market- by Drugs
10.4.6.2.3 Saudi Arabia Blood Cancer Drugs Market- by Treatment Approaches
10.4.6.3 U.A.E Blood Cancer Drugs Market-
10.4.6.3.1 U.A.E Blood Cancer Drugs Market- by Blood Cancer Types
10.4.6.3.2 U.A.E Blood Cancer Drugs Market- by Drugs
10.4.6.3.3 U.A.E Blood Cancer Drugs Market- by Treatment Approaches
10.4.6.4 Rest of Middle East and Africa Blood Cancer Drugs Market-
10.4.6.4.1 Rest of Middle East and Africa Blood Cancer Drugs Market- by Blood Cancer Types
10.4.6.4.2 Rest of Middle East and Africa Blood Cancer Drugs Market- by Drugs
10.4.6.4.3 Rest of Middle East and Africa Blood Cancer Drugs Market- by Treatment Approaches
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Blood Cancer Drugs Market- Overview
10.5.2 South and Central America Blood Cancer Drugs Market- Forecasts and Analysis
10.5.3 South and Central America Blood Cancer Drugs Market- Forecasts and Analysis - By Blood Cancer Types
10.5.4 South and Central America Blood Cancer Drugs Market- Forecasts and Analysis - By Drugs
10.5.5 South and Central America Blood Cancer Drugs Market- Forecasts and Analysis - By Treatment Approaches
10.5.6 South and Central America Blood Cancer Drugs Market- Forecasts and Analysis - By Countries
10.5.6.1 Brazil Blood Cancer Drugs Market-
10.5.6.1.1 Brazil Blood Cancer Drugs Market- by Blood Cancer Types
10.5.6.1.2 Brazil Blood Cancer Drugs Market- by Drugs
10.5.6.1.3 Brazil Blood Cancer Drugs Market- by Treatment Approaches
10.5.6.2 Argentina Blood Cancer Drugs Market-
10.5.6.2.1 Argentina Blood Cancer Drugs Market- by Blood Cancer Types
10.5.6.2.2 Argentina Blood Cancer Drugs Market- by Drugs
10.5.6.2.3 Argentina Blood Cancer Drugs Market- by Treatment Approaches
10.5.6.3 Rest of South and Central America Blood Cancer Drugs Market-
10.5.6.3.1 Rest of South and Central America Blood Cancer Drugs Market- by Blood Cancer Types
10.5.6.3.2 Rest of South and Central America Blood Cancer Drugs Market- by Drugs
10.5.6.3.3 Rest of South and Central America Blood Cancer Drugs Market- by Treatment Approaches
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL BLOOD CANCER DRUGS MARKET-
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. BLOOD CANCER DRUGS MARKET-, KEY COMPANY PROFILES
13.1. JOHNSON AND JOHNSON INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. AMGEN INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. BAYER AG.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. PFIZER, INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. ABBVIE INC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. ROCHE HOLDING AG.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. CELGENE CORPORATION
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. ASTRAZENECA
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. NOVARTIS AG
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. GLAXOSMITHKLINE PLC
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Johnson & Johnson Inc.
2. Amgen Inc.
3. Bayer AG.
4. Pfizer, Inc.]
5. AbbVie Inc.
6. Roche Holding AG.
7. Celgene Corporation
8. AstraZeneca
9. Novartis AG
10. GlaxoSmithKline PLC
TIPRE00019607
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.